Dialog window

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Dialog window

Jennifer Porter, BA Psychology, MBA – President & CEO

​Having started at Focal Point Research in 2011, Jenn has been fully engaged in the company and since day one, has leveraged her MBA and interest in the regulated products industries to grow her passion for the business and services offered. 

Jenn has excelled at building on initial conversations with a variety of companies from all industries seeking regulatory and quality assurance services. She has developed strong relationships with each client, offering each one a unique opportunity to have the Focal Point Research team help them develop successful strategies and bring products to market, while ensuring their compliance needs are being fulfilled. 

Jenn has not only been a leader internally, but a key contact for all clients and in 2021, Jenn was the obvious choice to lead Focal Point Research into the future as the successor to company founder, Rob Fichtner.

Jennifer balances her career by honouring her wanderlust, spending her leisure time golfing, and enjoying the outdoors with her loving dog.

(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
      • Natural Health Products
      • Topical OTC Drugs
      • Medical Devices
      • Consumer Products
      • FDA Consulting
    • Health Canada Consultants
      • Regulatory Affairs
      • Pharmacovigilance Services
      • MoCRA
      • Ingredient Compliance
      • CEPA
  • Innovation
  • Articles
  • Contact
Select Page
Implementation and Updates to the USMCA

Implementation and Updates to the USMCA

by Jenn Porter | Jul 8, 2020 | Canadian Regulatory, Natural Health Products, OTC Drugs, U.S. Regulatory

As of July 1st, the United-States-Mexico-Canada Agreement or USMCA has officially begun being implemented. As such, it would be best to discuss the details and what this agreement means for stakeholders.  ...
The Health and Safety of Avoiding Insect Bites

The Health and Safety of Avoiding Insect Bites

by Jenn Porter | Jul 2, 2020 | Canadian Regulatory, U.S. Regulatory

Although the incoming warm weather is welcomed by most, the insects that come with the weather are not as welcomed. Many people use insect repellent to aid in deterring insects and preventing irritating bites that may come with them. Insect repellent was originally...
Protecting Your Skin in the Sunny Weather

Protecting Your Skin in the Sunny Weather

by Jenn Porter | Jun 18, 2020 | Canadian Regulatory, Natural Health Products, OTC Drugs, U.S. Regulatory

As most people are aware, the sun’s ultraviolet (UV) rays are harmful to the skin year round. However, as the warm weather invites people to spend more time outdoors, people are more exposed to the harmful UV rays. Increased exposure to UV...
Health Canada: Mandatory Use of New Regulatory Enrolment Process for Drug Submissions

Health Canada: Mandatory Use of New Regulatory Enrolment Process for Drug Submissions

by Jenn Porter | May 12, 2020 | Canadian Regulatory, OTC Drugs, Research/Science/Technology, U.S. Regulatory, Uncategorized

Recently, Health Canada announced that the Regulatory Enrolment Process (REP) will be mandatory to use as of October 1, 2020. The Health Products and Food Branch (HPFB) will be implementing this single window for transmission of regulatory transactions in electronic...
Cannabis in Cosmetics; Where Are We Now

Cannabis in Cosmetics; Where Are We Now

by Jenn Porter | Apr 28, 2020 | Canadian Regulatory, Cosmetics, Innovation, Natural Health Products, OTC Drugs, Research/Science/Technology, U.S. Regulatory

A couple of years ago the world began legalizing recreational cannabis, bringing it into the cosmetic industry. Since then, it has been reported that the cosmetic CBD market has a net worth of 710 million US dollars and is projected to have a net worth of 959 million...
A Summary of International Efforts in Minimizing the Spread of COVID-19

A Summary of International Efforts in Minimizing the Spread of COVID-19

by Jenn Porter | Apr 3, 2020 | Canadian Regulatory, Innovation, Medical Devices, Research/Science/Technology, U.S. Regulatory

Recently, information has been provided regarding updates that Health Canada and the U.S. FDA have done in order to aid in the battle against COVID-19. However, other countries have also taken drastic measures to assist with reducing the spread of COVID-19. The...
« Older Entries
Next Entries »

Recent Posts

  • Illinois Proposed Ban on Nonbiodegradable Plastic Glitter
  • Washington State TFCA Sell-Through Period Expires December 31
  • Health Canada Proposed Updates to the Cosmetic Ingredient Hotlist
  • Updates on Amendment and Notification Applications for Site Licences
  • Health Canada Opens Consultation on Draft Guidance for Drug and Natural Health Product Summary Reports

Recent Comments

    Archives

    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • June 2025
    • May 2025
    • March 2025
    • October 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • December 2023
    • November 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • January 2023
    • December 2022
    • November 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • October 2021
    • July 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • California Cosmetic Regulations
    • California Office of Environmental Health Hazard Assessment
    • Canadian Quality Assurance
    • Canadian Regulatory
    • Cosmetic Ingredient Hotlist
    • Cosmetics
    • Cosmetics
    • Environment and Climate Change Canada
    • European Regulatory
    • Events/Company Updates
    • FDA
    • Federal Plastics Registry
    • Health Canada Updates
    • Importation of NHPs
    • Innovation
    • Medical Device
    • Medical Devices
    • MoCRA
    • Natural Health Products
    • New Mexico
    • OTC Drugs
    • Our View
    • Prop 65
    • Research/Science/Technology
    • Toxic-Free Cosmetics Act
    • U.S. Regulatory
    • U.S. State Updates
    • Uncategorized
    Copyright © 2025 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY